TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05326685

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video with korotkoff sounds
Description: The State-Trait Anxiety Inventory short version (STAIS-5, STAIT-5) and the student introduction form were applied at the beginning of the study. Then Intervention participants were shown and listened visual video with korotkoff sounds before blood presssure measurement. Afterwards, blood pressure was measured to the students 3 times and 3 measurements were recorded. After the application about 2 hours later, the students State Anxiety Inventory short version (STAIS-5) form was filled again by students.
Study: NCT05959902

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Forward Walking
Description: During the 8-week treatment, the participants will undertake 10 minutes of forward walking, as well as a 5-minute warm-up and cool-down, three times a week on an even surface at their normal speed as a home exercise plan. During the warmup and cool down periods, the participants were advised to execute ankle toe motions, heel lift exercises, and hamstring and gastrocnemius-soleus stretches.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy Exercises
Description: Isometric quadriceps exercise. Straight leg raising (SLR) exercise. Isometric hip adduction exercise.~Terminal knee extension exercise:~Semi-wall squat exercise. Quadriceps drill exercise.
Study: NCT04361617

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Daily consumption of tree nuts and extra virgin olive oil
Description: All participants will receive a 4-week supply of extra virgin olive oil and tree nuts, including unsalted English walnuts, almonds or pistachios (approximately 3-day supply of each type). Participants will be asked to include in their normal diets these products and will be provided recipes and other information that will allow them to replace other foods with the nuts and oil. We will ask participants to consume one ounce of tree nuts per day and two tablespoons of EVOO per day by incorporating these foods into their diet.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Daily consumption of tree nuts and extra virgin olive oil
Description: All participants will receive a 4-week supply of extra virgin olive oil and tree nuts, including unsalted English walnuts, almonds or pistachios (approximately 3-day supply of each type). Participants will be asked to include in their normal diets these products and will be provided recipes and other information that will allow them to replace other foods with the nuts and oil. We will ask participants to consume one ounce of tree nuts per day and two tablespoons of EVOO per day by incorporating these foods into their diet.
Study: NCT05281081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intraperitoneal levobupivacaine and morphine
Description: istillation of the peritoneum with levobupivacaine mixture with morphine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intraperitoneal levobupivacaine and morphine
Description: istillation of the peritoneum with levobupivacaine mixture with morphine
Study: NCT06418347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha lipoic acid
Description: Alpha-lipoic acid (ALA), also known as 1,2-dithiolane-3-pentanoic acid or thioctic acid, is found in the mitochondria. It acts as an enzymatic cofactor for various enzymes in the Kreb's cycle. ALA has many beneficial properties making it a potential candidate for various clinical disorders. It is considered the universal or ideal antioxidant as it is both water-soluble and fat-soluble facilitating its passage across membran. ALA has direct as well as indirect anti-inflammatory effects. Being a potent antioxidant leads to a reduction in oxidative stress which in turn reduces inflammation, meaning ALA indirectly has anti-inflammatory effects. To add to ALA's benefits, it has anti-inflammatory properties that are independent of its antioxidant effects.

Intervention type: DRUG
Group type: OTHER
Intervention: Letrozole
Description: Letrozole is an aromatase inhibitor that controls the conversion of androgen to estrogen and increases ovarian androgens. The administration of letrozole in the follicular phase removes the effect of negative estrogen feedback on the pituitary and hypothalamus, thus increasing the gonadotropins\]. When Letrozole blocks estrogen production, it encourages the body to produce more follicle-stimulating hormone (FSH).The additional FSH stimulates egg development and increases the likelihood of ovulation. Kar, S. Found that letrozole has excellent pregnancy rates compared to clomiphene citrate, Letrozole should be considered at par with clomiphene citrate as first-line drug for ovulation induction in infertile PCOS women.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole is an aromatase inhibitor that controls the conversion of androgen to estrogen and increases ovarian androgens. The administration of letrozole in the follicular phase removes the effect of negative estrogen feedback on the pituitary and hypothalamus, thus increasing the gonadotropins\]. When Letrozole blocks estrogen production, it encourages the body to produce more follicle-stimulating hormone (FSH).The additional FSH stimulates egg development and increases the likelihood of ovulation. Kar, S. Found that letrozole has excellent pregnancy rates compared to clomiphene citrate, Letrozole should be considered at par with clomiphene citrate as first-line drug for ovulation induction in infertile PCOS women.
Study: NCT05198180

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical 30%Potassium hydroxide solution
Description: Patients will apply the solution every day under occlusion for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical 45% hydrogen peroxide solution
Description: Patients will apply the solution every day under occlusion
Study: NCT04832022

Intervention type: OTHER
Intervention: Biological samples
Description: Serum and plasma samples. At baseline, 3, 6 and 12 months

Intervention type: OTHER
Intervention: Biological samples
Description: Serum and plasma samples. At baseline, 3, 6 and 12 months
Study: NCT05858112

Intervention type: DIAGNOSTIC_TEST
Intervention: SuperTROPO novel assay to measure the long forms of cTnT
Description: SuperTROPO novel assay to measure the long forms of cTnT
Study: NCT04736134

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986326
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986326
Description: Specified dose on specified days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching BMS-986326
Description: Specified dose on specified days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching BMS-986326
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multiple Ascending Dose SC
Description: Specified dose on specified days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Multiple Ascending Dose Placebo
Description: Specified dose on specified days
Study: NCT06156501

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACL Reconstruction
Description: Reconstruction of the anterior cruciate ligament
Study: NCT04859452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DBPR108 tablets
Description: Drug: DBPR108, tablet, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DBPR108 tablets
Description: Drug: DBPR108, tablet, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DBPR108 tablets
Description: Drug: DBPR108, tablet, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DBPR108 tablets
Description: Drug: DBPR108, tablet, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin hydrochloride tablets
Description: Drug: Metformin hydrochloride, tablet, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glibenclamide tablets
Description: Drug: Glibenclamide, tablet, oral
Study: NCT06124820

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deka SmartXide Touch C60 (MonaLisa Touch)
Description: Intravaginal micro-ablative fractional CO2 laser technology Deka SmartXide Touch C60 (MonaLisa Touch)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Participants receiving sham treatment will have the probes advanced in the same manner without the use of a laser energy device.
Study: NCT05097352

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIIT)
Description: Twenty minutes of HIIT will be completed three days a week for six weeks.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Waitlist
Description: Waitlist participants will be tested on the outcomes at the same time points as the treatment group.
Study: NCT04859452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan Capsules
Description: Drug: Valsartan, capsule, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin tablets
Description: Drug: Simvastatin, tablet, oral
Study: NCT05955183

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD5055
Description: AZD5055 will be given orally to randomized participants as per the arm they are assigned.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AZD5055
Description: AZD5055 will be given orally to randomized participants as per the arm they are assigned.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo will be given orally to randomized participants as per the arm they are assigned.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given orally to randomized participants as per the arm they are assigned.
Study: NCT04447898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPV-06 10 μg
Description: Low dose + Montanide™ ISA 51 VG in SC administration = 3 injections on Day 0, Day 28, and Day 112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPV-06 50 μg
Description: High dose+ Montanide™ ISA 51 VG in SC administration = 3 injections on Day 0, Day 28, and Day 112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo+ Montanide™ ISA 51 VG in SC administration = 3 injections on Day 0, Day 28, and Day 112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo+ Montanide™ ISA 51 VG in SC administration = 3 injections on Day 0, Day 28, and Day 112
Study: NCT06353698

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fasting mimicking diet
Description: Fasting mimicking diet is limited calorie diet to enhance the effectiveness of chemotherapy
Study: NCT05568667

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low risk
Description: * remote support in physical activity and nutrition via digital media~* monthly collective physical activity sessions~* logbook

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate risk
Description: * remote support in physical activity and nutrition via digital media~* monthly collective physical activity sessions~* one collective health education session~* logbook

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High risk
Description: * remote support in physical activity and nutrition via digital media~* monthly collective physical activity sessions~* one collective health education session~* 3 individual sessions of motivational coaching~* connected watch~* logbook
Study: NCT04966689

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: combined speech and music therapy
Description: he telerehabilitation intervention that include both speech therapy and music therapy at the same time

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: speech therapy
Description: A behavioural speech therapy program including breathing exercises, loudness, pitch, and intelligibility which are adapted from Lee Silverman Voice Treatment (LSVT) and voice exercises Which is delivered through telerehabilitation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: music therapy
Description: music exercises Will be designed based on the music therapy protocols of previous studies Which is delivered through telerehabilitation
Study: NCT03992092

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-MAC VS
Description: C-MAC Video Stylet

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flexible Bronchoscopy
Description: Flexible Bronchoscopy
Study: NCT06004570

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Complex product
Description: Extracts from the fruits of Vaccinium myrtillus L. + Aronia Melanocarpa (Michx.) Elliot + Lonicera caerulea var. Kamtschatica, rutin, vitamin B6, vitamin B12, folic acid Single oral dose - 2 capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Polyphenol-rich extracts
Description: Extracts from the fruits of Vaccinium myrtillus L. + Aronia Melanocarpa (Michx.) Elliot + Lonicera caerulea var. Kamtschatica Single oral dose - 2 capsules

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single oral dose - 2 capsules
Study: NCT06065436

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Collagenase Clostridium Histolyticum
Description: Total of 8 Intralesional injection (0.90 mg), administered as four separate injection series. Within each series, subjects will receive two injections, administered approximately 1-7 days apart.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Collagenase Clostridium Histolyticum
Description: Total of 8 Intralesional injection (0.90 mg), administered as four separate injection series. Within each series, subjects will receive two injections, administered approximately 1-7 days apart.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Storz Duolith LiSWT
Description: Single low intensity shockwave therapy consistent of 1,500 shocks at a rate of 120 shocks/minute and using a power setting of 0.09 mJ/mm2. These treatments will occur four separate times, before each of the four separate CCH injection series.
Study: NCT04958226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capivasertib
Description: Capivasertib (tablet) will be given as an intermittent schedule (4 days on/3 days off) from Cycle 1 Day 2 until discontinuation. Capivasertib will be administrated in both Part A and Part B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Single doses of midazolam (syrup, 1 mg) will be given on cycle 1 Days 1, 8, and 12.
Study: NCT06259890

Intervention type: OTHER
Group type: OTHER
Intervention: measurement of salt intake
Description: measurement of salt intake without intervention
Study: NCT04907045

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Coaching
Description: The clinic is provided access to a health coach who conducts outreach with patients. The health coach facilitates engagement with the digital therapeutic and encourages contact with the care team.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Coaching
Description: The clinic is provided access to a health coach who conducts outreach with patients. The health coach facilitates engagement with the digital therapeutic and encourages contact with the care team.
Study: NCT05771688

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FETO therapy
Description: placement of FETO prior to 29 weeks 6 days GA; and removal of the FETO device no later than 35 weeks and 6 days
Study: NCT06395207

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Proactive community case management
Description: Community health workers conduct proactive visits to households in their community every two weeks for two months to screen for fever and test and treat febrile individuals for malaria.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Strengthened SBCC and stock out mitigation
Description: Ensure CHWs have all commodities needed for malaria testing and treatment and are adequately trained on SBCC messages to ensure activities are implemented as designed in the national strategy.
Study: NCT04907045

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Practice Facilitation
Description: In the context of a supportive relationship, a trained facilitator delivers the following interventions to clinic staff: Bolster Education, Audit and Provide Feedback, Support Plan-Do-Study-Act Cycles, Engage Others in Change.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Implementation
Description: Brief clinician training and an implementation toolkit consisting of job aids, patient educational materials, scripted conversations, electronic health record tools, and a population management workbench.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Implementation
Description: Brief clinician training and an implementation toolkit consisting of job aids, patient educational materials, scripted conversations, electronic health record tools, and a population management workbench.
Study: NCT04808973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir plus lamivudine in a FDC
Description: All participants will receive an ART regimen composed by Lamivudine plus Dolutegravir in a single pill (FDC)
Study: NCT05299528

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Direct Feedback
Description: Procedure-specific direct feedback will be provided to surgeon participants through electronic and written communication, on patients' opioid consumption-to-prescription ratio. Surgeon participants who perform more than 1 of the specified procedures will receive nudging communications for each individual procedure.
Study: NCT04934059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yuxuebi tablet
Description: 0.5g/ tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: 0.5g/ tablet
Study: NCT05963802

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence (ChatGPT) Group
Description: Participants in Group A will be assigned to utilize ChatGPT as their tool to complete assignments. They will be given a period of six days to utilize artificial intelligence through ChatGPT for assignment completion. Along with the assignment instructions, participants will receive an ethical guideline and specific guidelines on how to effectively utilize ChatGPT. Once the intervention period is concluded, participants will be given a 24-hour window to complete a survey that assesses the usability of the technology. The survey aims to gather valuable feedback on the participants' experience and perception of using ChatGPT for their assignments. In addition, participants in Arm 1 will also be asked to fill out a survey regarding their perception of using artificial intelligence (AI) as an assistance tool to complete their assignments. This survey aims to gather insights into their thoughts, opinions, and attitudes towards utilizing AI in the learning process.
Study: NCT06139302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550
Description: BI 1015550
Study: NCT03975361

Intervention type: OTHER
Group type: OTHER
Intervention: Bliss-Believe
Description: The samples from the blood samples carried out within the framework of Bliss Believe will be collected for a biological collection. Only one sample of patients included in BLISS BELIEVE STUDY will be obtained during a standard of care visit. It will be 21ml of blood.
Study: NCT04878809

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Escola L'Horitzó
Description: Diagnosis of SARS-CoV-2 infection by rapid antigen detection tests in nasal and nasopharyngeal swabs, in asymptomatic and symptomatic subjects who attend regularly to L'Horitzó school .

Intervention type: OTHER
Group type: OTHER
Intervention: Escola John Talabot
Description: John Talabot School will provide the incidence of infection by SARS-CoV-2 in order to compare the incidence of infection from L'Horitzó School.
Study: NCT06455072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nituzumab
Description: EGFR monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab
Description: PD-1 (programmed death receptor 1) monoclonal antibody
Study: NCT05605158

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone 30mg
Description: Pioglitazone 30 mg will be administered orally once daily for 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 10 MG
Description: Empagliflozin 10 mg will be administered orally once daily for 24 weeks.
Study: NCT06425289

Intervention type: OTHER
Intervention: Macrohemodynamic parameters
Description: Macrohemodynamic parameters will be estimated with transpulmonary thermodilution every 6 hours during the intervention period (5 days).~* Cardiac index~* Extravascular lung water index~* Pulmonary vascular permeability index~* Cardiac function index~* Global end-diastolic volume index~* Central venous pressure~* Fluid responsivness status (passive leg rising test)

Intervention type: OTHER
Intervention: Macrohemodynamic parameters
Description: Macrohemodynamic parameters will be estimated with transpulmonary thermodilution every 6 hours during the intervention period (5 days).~* Cardiac index~* Extravascular lung water index~* Pulmonary vascular permeability index~* Cardiac function index~* Global end-diastolic volume index~* Central venous pressure~* Fluid responsivness status (passive leg rising test)
Study: NCT06509555

Intervention type: OTHER
Intervention: non-intervention
Description: non-intervention

Intervention type: OTHER
Intervention: non-intervention
Description: non-intervention
Study: NCT05344742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride Liposome injection
Description: Mitoxantrone hydrochloride liposome injection will be administered intravenously once every 3 weeks (a cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride Liposome injection
Description: Mitoxantrone hydrochloride liposome injection will be administered intravenously once every 3 weeks (a cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: The fixed dose of oral capecitabine will be administered 1000mg/m\^2, twice daily, from day 1 to day 14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-paclitaxel
Description: The fixed dose of albumin-paclitaxel will be set as 260 mg/m\^2, once every three weeks.
Study: NCT05198219

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambu® aScope™ 4 Rhinolaryngo
Description: Patient indication following a rhinolaryngoscopy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional reusable rhinolaryngoscope
Description: Patient indication following a rhinolaryngoscopy
Study: NCT05914532

Intervention type: OTHER
Intervention: lab testing
Description: Complete blood count and erythrocyte sedimentation rate and C-reactive protein values of the participants were analyzed by laboratory test.

Intervention type: OTHER
Intervention: lab testing
Description: Complete blood count and erythrocyte sedimentation rate and C-reactive protein values of the participants were analyzed by laboratory test.